Miyoshi Yasuhide, Yoneyama Shuko, Kawahara Takashi, Hattori Yusuke, Teranishi Jun-Ichi, Ohta Jun-Ichi, Takebayashi Shigeo, Yokomizo Yumiko, Hayashi Narihiko, Uemura Hiroji
Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
Urol Int. 2017;99(4):400-405. doi: 10.1159/000477131. Epub 2017 Jun 14.
We evaluated bone scan index (BSI) as a predictive biomarker for time to castration-resistant prostate cancer (CRPC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
We identified 85 consecutive mHSPC patients treated with first-line androgen deprivation therapy. We analyzed the correlations between time to CRPC and clinicopathological characteristics, including age, prostate-specific antigen (PSA) level, Gleason score, clinical TNM stage, hemoglobin, lactate dehydrogenase, C-reactive protein, and BSI.
The median BSI was 2.7%. Progression to CRPC occurred in 55 (64.7%) patients and the median time to CRPC was 12.9 months. In multivariate analysis, 3 significant risk factors for time to CRPC were identified: age (>73 vs. ≤73 years; hazard ratio [HR] 0.53), p = 0.038, PSA level (>270 vs. ≤270 ng/mL; HR 0.53, p = 0.038), and BSI (>2.7 vs. ≤2.7%; HR 2.97, p < 0.001).
Age, PSA level, and BSI were found to be significant predictive factors for time to CRPC in patients with mHSPC.
我们评估了骨扫描指数（BSI）作为转移性激素敏感性前列腺癌（mHSPC）患者去势抵抗性前列腺癌（CRPC）发生时间的预测生物标志物。
我们确定了85例接受一线雄激素剥夺治疗的连续mHSPC患者。我们分析了CRPC发生时间与临床病理特征之间的相关性，包括年龄、前列腺特异性抗原（PSA）水平、 Gleason评分、临床TNM分期、血红蛋白、乳酸脱氢酶、C反应蛋白和BSI。
BSI中位数为2.7%。55例（64.7%）患者进展为CRPC，CRPC发生的中位时间为12.9个月。在多变量分析中，确定了CRPC发生时间的3个显著风险因素：年龄（>73岁 vs. ≤73岁；风险比[HR] 0.53），p = 0.038，PSA水平（>270 vs. ≤270 ng/mL；HR 0.53，p = 0.038），以及BSI（>2.7 vs. ≤2.7%；HR 2.97，p < 0.001）。
年龄、PSA水平和BSI被发现是mHSPC患者CRPC发生时间的显著预测因素。
